We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.43%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$240M
Cap. Flow
+$114M
Cap. Flow %
4.13%
Top 10 Hldgs %
48.06%
Holding
144
New
27
Increased
15
Reduced
14
Closed
28

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$58.4M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$54.6M
3
JNJ icon
Johnson & Johnson
JNJ
+$45.1M
4
ALKS icon
Alkermes
ALKS
+$27.4M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$24.1M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$72.5M
2
GILD icon
Gilead Sciences
GILD
+$21.9M
3
PRGO icon
Perrigo
PRGO
+$21.6M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$19.4M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$9.46M

Sector Composition

Rank Sector Weight
1 Healthcare 84.12%
2 Real Estate 3.08%
3 Financials 1.53%
4 Technology 0.04%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IPCI
101
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$1.04M 0.04%
35,405
-103,995
-75% -$3.14M
LKFT
102
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$1.03M 0.04%
+20,000
New +$1.06M
SGMO
103
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$832K 0.03%
75,000
-604,100
-89% -$7.79M
CDTX
104
DELISTED
Cidara Therapeutics
CDTX
$701K 0.03%
+2,500
New +$769K
ADAP
105
DELISTED
Adaptimmune Therapeutics
ADAP
$504K 0.02%
+27,500
New +$472K
MGNX icon
106
MacroGenics
MGNX
$240M
$484K 0.02%
12,743
– –
LRMR icon
107
Larimar Therapeutics
LRMR
$398M
$461K 0.02%
1,109
– –
XNCR icon
108
Xencor
XNCR
$1.59B
$439K 0.02%
20,000
– –
KITE
109
DELISTED
Kite Pharma, Inc.
KITE
$384K 0.01%
6,300
-40,200
-86% -$2.29M
ACHV icon
110
Achieve Life Sciences
ACHV
$647M
$264K 0.01%
51
– –
ABBV icon
111
AbbVie
ABBV
$455B
$10K ﹤0.01%
156
-1,110,458
-100% -$72.5M
ABBV icon
112
CALL
AbbVie
ABBV
$455B
– –
-200,000
Closed -$11.7M
AGIO icon
113
Agios Pharmaceuticals
AGIO
$1.95B
– –
-100,300
Closed -$9.46M
ALNY icon
114
CALL
Alnylam Pharmaceuticals
ALNY
$27.4B
– –
-54,300
Closed -$5.67M
ARAY icon
115
Accuray
ARAY
$33.9M
– –
-731,943
Closed -$6.81M
BIIB icon
116
CALL
Biogen
BIIB
$30.7B
– –
-12,200
Closed -$5.15M
CARM
117
DELISTED
Carisma Therapeutics
CARM
– –
-9,798
Closed -$1.75M
CRDF icon
118
Cardiff Oncology
CRDF
$66.2M
– –
-9,028
Closed -$4.43M
CYH icon
119
CALL
Community Health Systems
CYH
$391M
– –
-60,500
Closed -$2.61M
GILD icon
120
CALL
Gilead Sciences
GILD
$163B
– –
-430,100
Closed -$42.2M
ILMN icon
121
CALL
Illumina
ILMN
$31B
– –
-30,223
Closed -$5.46M
INCY icon
122
CALL
Incyte
INCY
$24.9B
– –
-56,000
Closed -$5.13M
MYGN icon
123
CALL
Myriad Genetics
MYGN
$507M
– –
-74,800
Closed -$2.65M
PRGO icon
124
CALL
Perrigo
PRGO
$1.43B
– –
-67,700
Closed -$11.2M
PRGO icon
125
Perrigo
PRGO
$1.43B
– –
-130,652
Closed -$21.6M
2 3 4
5
6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Tekla Capital Management held 144 positions worth $2.76B, up 9.5% from $2.52B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Tekla Capital Management deployed $114M of net new capital in Q2 2015, opening 27 new positions and adding to 15 existing holdings. Its largest new stake was Humana: 112,000 shares worth $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was AbbVie, an estimated $72.5M trimmed.

  • Tekla Capital Management's largest Q2 2015 buy was Humana: 112,000 shares worth $21.4M.
  • Tekla Capital Management added most to Viatris in Q2 2015, an estimated $58.4M increase.
  • Tekla Capital Management's biggest Q2 2015 reduction was AbbVie, cutting an estimated $72.5M.
  • Tekla Capital Management fully exited Perrigo in Q2 2015, selling an estimated $21.6M.
  • Tekla Capital Management's ten largest holdings make up 48% of its $2.76B portfolio in Q2 2015.
  • Tekla Capital Management opened 27 new positions and closed 28 in Q2 2015.
  • Tekla Capital Management's portfolio value rose 9.5% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.